BeyondSpring Inc. Deferred Offering Costs
BeyondSpring Inc. (BYSI) had Deferred Offering Costs of $0 as of 2017-06-30, per its 6-K filed 2017-08-21.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2018-04-03
- 2017-06-30: Deferred Offering Costs $0.00.
- 2017-03-31: Deferred Offering Costs $0.00.
- 2016-12-31: Deferred Offering Costs $1.86M.
| Period end | Deferred Offering Costs |
|---|---|
| 2017-06-30 | $0.00 6-K · filed 2017-08-21 |
| 2017-03-31 | $0.00 6-K · filed 2017-05-22 |
| 2016-12-31 | $1.86M 20-F · filed 2018-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |